Truist raises Nurix Therapeutics price target to $32
Truist Securities analyst Gregory Renza maintained a Buy rating on Nurix Therapeutics, raising the price target to $32 from the previous $30.

*this image is generated using AI for illustrative purposes only.
Truist Securities analyst Gregory Renza has maintained a Buy rating on Nurix Therapeutics and raised the price target for the stock. The new target of $32 represents an increase from the previous $30.
Rating and Target Update
The analyst's decision to maintain the Buy rating accompanies the revised price objective. The adjustment reflects a positive outlook on the company's performance.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $30 |
| New Price Target | $32 |
What specific catalysts or data points are expected to drive the stock toward the new $32 price target?
How might this rating update influence investor sentiment and trading volume in the short term?
What are the potential risks or market conditions that could prevent Nurix Therapeutics from meeting this revised target?

























